ABSTRACT
OBJECTIVE, AND MATERIAL AND METHODS: A systematic review and meta-analysis was performed to evaluate the effectiveness of antidepressants in reducing the poor evolution of COVID-19 disease (a composite variable including death, hospitalization and need for mechanical ventilation), and mortality, according the guidelines for Systematic Reviews of Interventions published by the Cochrane library. SOURCE OF DATA: MEDLINE, EMBASE and COCHRANE LIBRARY were consulted up to February 25, 2022. Unpublished studies were searched on clinicaltrials.gov platform. SELECTION OF STUDIES: Seven masked and unmasked, observational and experimental studies evaluating death, hospitalization and need for mechanical ventilation were selected. A second subgroup analysis with mortality variable was performed. DATA EXTRACTION: A full risk of bias assessment was performed addressing issues such as information and confounding bias. ROB2 and Robins-I tools for randomized and no randomized studies were employed respectively. In the quantitative analysis, the risk of publication bias, heterogeneity, estimation of pooled measure and a sensitivity analysis was performed. The pooled final measure was calculated as odds ratio with its correspondent 95% confidence interval. A random effects model was used for this purpose due to the heterogeneity between included studies. Finally, a sensitivity analysis was performed to assess the robustness of final pooled measure. RESULTS: Seven studies were finally considered to calculate the final pooled measure. The effect of intervention was OR 0.73; 95% CI 0.56-0.94. CONCLUSIONS: The use of antidepressants, and specially SSRI could be effective for reducing the risk of poor progression of COVID-19 disease.
Subject(s)
COVID-19 , Humans , Prognosis , Antidepressive Agents/therapeutic use , Hospitalization , Odds RatioABSTRACT
La concurrencia de depresión y un trastorno por uso de sustancias (TUS) en pacientes que presentan patología dual ha sido reconocida desde hace mucho tiempo como una consideración importante en la práctica clínica. Esta revisión sintetiza la evidencia de intervenciones farmacológicas y psicosociales para trastornos comórbidos de depresión y uso de sustancias y además proporciona recomendaciones clínicas respecto de las mejores intervenciones para tratar a estos pacientes. Se utilizó la mejor evidencia de ensayos controlados aleatorizados para evaluar las opciones de tratamiento. La fuerza de las recomendaciones se describió mediante el enfoque GRADE.(AU)
Co-occurrence of depression and a substance use disorder (SUD) in patients who present dual diagnoses has been long recognized as an important consideration in clinical practice. This review synthesizes the evidence of pharmacological and psychosocial interventions for comorbid depressive disorders and SUDs while providing clinical recommendations about the best interventions to address these patients. The best evidence from randomized controlled trials was used to evaluate treatment options. The strength of recommendations was described using the GRADE approach.(AU)
Subject(s)
Practice Guideline , Pharmacology , Depressive Disorder , Substance-Related DisordersABSTRACT
Esta revisión resume las intervenciones farmacológicos y psicosociales que han sido llevadas a cabo en trastornos de ansiedad con un diagnóstico comórbido de trastorno por uso de sustancias y además proporciona recomendaciones clínicas respecto de cuáles elementos de intervención son útiles para hacer frente a los síntomas del uso de sustancias y los síntomas de ansiedad en pacientes con estas afecciones concurrentes. Se utilizó la mejor evidencia de ensayos controlados aleatorizados para evaluar las opciones de tratamiento. La fuerza de las recomendaciones se describió mediante el enfoque GRADE. Hay ensayos clínicos disponibles únicamente para el trastorno por estrés postraumático (TEPT) y para el trastorno de ansiedad. En cuanto al diagnóstico comórbido de trastorno por uso de sustancias, todos los estudios han incluido pacientes con consumo de alcohol, ninguno de ellos ha abordado el consumo de cocaína, cannabis o nicotina. Aunque algunos tratamientos han mostrado beneficios para los síntomas de ansiedad sin beneficios para el consumo de alcohol u otras sustancias, solo se han ensayado enfoques farmacológicos limitados (sertralina, desipramina, paroxetina, buspirona, naltrexona y disulfiram).(AU)
This review synthesizes the pharmacological and psychosocial interventions that have been conducted in comorbid anxiety disorders and SUDs while also providing clinical recommendations about which intervention elements are helpful for addressing substance use versus anxiety symptoms in patients with these co-occurring conditions. The best evidence from randomized controlled trials was used to evaluate treatment options. The strength of recommendations was described using the GRADE approach. Clinical trials are only available for post-traumatic stress disorder (PTSD) and for social anxiety. Concerning the comorbid substance use, all the studies have included patients with alcohol use, none of them have dealt with cocaine, cannabis or nicotine use. Although some treatments have shown benefit for anxiety symptoms without benefits for alcohol or other substance use, only limited pharmacological approaches have been assayed (sertraline, desipramine, paroxetine, buspirone, naltrexone and disulfiram).(AU)
Subject(s)
Humans , Adult , Practice Guidelines as Topic , Pharmacology , Substance-Related Disorders , Anxiety DisordersABSTRACT
RESUMEN Los trastornos vestibulares funcionales se constituyen como una de las causas más frecuentes de consulta por vértigo y trastornos del equilibrio. El mareo postural perceptual persistente (MPPP) es un síndrome recientemente definido, enmarcado en la categoría de síndromes vestibulares crónicos, que agrupa trastornos vestibulares funcionales crónicos como el vértigo postural fóbico, el malestar con el movimiento espacial, el vértigo visual y el mareo subjetivo crónico. El MPPP se manifiesta por síntomas de mareo, inestabilidad y/o vértigo no rotatorio, persistentes, exacerbados por cambios posturales, movimientos y exposición a distintos estímulos visuales. El tratamiento de este cuadro es más sencillo de lo que parece, basado en psicoeducación efectiva respecto a la patología como primer abordaje, adicionando o no rehabilitación vestibular, uso de inhibidores selectivos de la recaptación de serotonina y/o terapia cognitivo conductual. Se presentan dos casos clínicos de pacientes diagnosticados con MPPP y su respuesta a tratamiento.
ABSTRACT Functional vestibular disorders are one of the most frequent causes of consultation due to vertigo and balance disorders. Persistent postural-perceptual dizziness (PPPD) is a recently defined syndrome, categorized as a chronic vestibular syndrome, that includes functional vestibular disorders such as phobic postural vertigo, space-motion discomfort, visual vertigo and chronic subjective dizziness. PPPD manifests with dizziness, unsteadiness and/or non-spinning vertigo, which are persistent, exacerbated by postural changes, movements and exposure to various visual stimuli. PPPD treatment is simpler than it may seem initially. It is based on effective psychoeducation related to the pathology in the first place, followed, or not, by vestibular rehabilitation, use of selective serotonin reuptake inhibitors and/or cognitive behavioral therapy. We present two clinical cases of patients diagnosed with PPPD and their response to treatment.
Subject(s)
Humans , Male , Female , Middle Aged , Dizziness/diagnosis , Dizziness/therapy , Posture , Visual Perception , Cognitive Behavioral Therapy , Vestibular Diseases , Chronic Disease , Selective Serotonin Reuptake Inhibitors/therapeutic use , Sertraline/therapeutic use , Dizziness/physiopathologyABSTRACT
Los antidepresivos inhibidores selectivos de la recaptación de serotonina son ampliamente utilizados en la práctica clínica y han desplazado a otros grupos de antidepresivos en las últimas décadas. Esto parece estar vinculado al concepto de su mayor perfil de seguridad y a la minimización de los potenciales efectos adversos que su uso podría generar. Sin embargo el número de efectos adversos tanto leves como graves reportados no son despreciables y es importante su conocimiento con el fin de evitar o diagnosticar en forma precoz y actuar en consecuencia
Selective serotonin receptor inhibitor are widely used in clinical practice and have moved to other antidepressive drugs in recent decades. This seems to be linked to the concept of their greater safety profile and to minimize potential adverse effects that their use could generate. However, the number of both minor and serious reported adverse effects are not negligible and knowledge is important in order to prevent or diagnose early and act accordingly
ABSTRACT
INTRODUCTION: Post-stroke depression (PSD) is the most common mood disorder following a stroke, and also the main factor limiting recovery and rehabilitation in stroke patients. In addition, it may increase mortality by up to ten times. DEVELOPMENT: PSD occurs in 1 in 3 stroke patients and more than half of all cases are neither diagnosed nor treated. Several mechanisms, including biological, behavioral, and social factors, are involved in its pathogenesis. Symptoms usually occur within the first three months after stroke (early onset PSD), and less frequently at a later time (late onset PSD). Symptoms resemble those of other types of depression, although there are some differences: PSD patients experience more sleep disturbances, vegetative symptoms, and social withdrawal. For PSD diagnosis, we recommended vigilance and use of specific diagnostic tools such as the Patient Health Questionnaire-2 (PHQ-2). The treatments of choice are selective serotonin reuptake inhibitors (SSRI). However, there are still many unanswered questions in the treatment of PSD, such as the best time to start treatment or the effects of antidepressants on cognition and motor function, among others. CONCLUSIONS: Neurologists play a pivotal role in the care and management of patients recovering from stroke. They must be familiar with methods for early detection and treatment of PSD, as this can facilitate a patient's functional recovery and social reintegration, and improve quality of life for patients and their families.
Subject(s)
Depression/diagnosis , Stroke/psychology , Antidepressive Agents/therapeutic use , Depression/drug therapy , Depression/etiology , Humans , Quality of Life , Selective Serotonin Reuptake Inhibitors/therapeutic use , Surveys and QuestionnairesABSTRACT
La eyaculación precoz o rápida (EP) constituye hoy, posiblemente la disfunción sexual más frecuente en el género masculino y está determinada por factores sociales, culturales y el establecimiento de métodos compensatorios. Es causante de serias afectaciones para la persona que la padece, ya sea en el plano social, psicológico o familiar. Su frecuencia es superior al de la disfunción eréctil, pero con mejores niveles de tolerancia. Entre los factores asociados a su aparición se encuentran causas biológicas, posibles endocrinopatías, predisposición genética y causas psicológicas. Entre las opciones terapéuticas se señalan los tratamientos psicoterapéuticos; desde las corrientes conductuales, agentes tópicos basados, en su gran mayoría, en Spray y cremas con componentes anestésicos. Otros como los tratamientos sistémicos se basan fundamentalmente en fármacos anestésicos y antidepresivos, así como la combinación de varios fármacos y métodos, lográndose entonces, mayores tasas de efectividad. Finalmente se propone en la actualidad la Dapoxetine, un antidepresivo (ISRS) con buenas tasas de respuesta. En el siguiente artículo se realizó una revisión del tema, profundizando en aspectos relacionados con la repuesta sexual masculina y su tratamiento. Con este objetivo se consultó los trabajos más actuales publicados en Pubmed y Medline.Conclusiones: La eyaculación rápida constituye un problema de salud a nivel mundial y pese a las variantes de tratamiento existentes todavía, se presenta resistencia masculina a su aceptación como trastorno y por tanto a su tratamiento. Los ISRS, y en especial la Dapoxetine, constituyen una variante de tratamiento efectiva(AU)
The premature ejaculation (PE) is nowadays probably the sexual dysfunction more frequent in the masculine sex and it is defined by social and cultural factors and the establishment of compensatory methods. Premature ejaculation causes several affections for the person who suffers from it in the social, psychological or family environment. Its frequency is higher than the dysfunction, but with better levels of acceptance. Among the associated factors that lead to its occurrence are the biological causes, the possible endocrinopathies, genetic tendency and psychological causes. Among the therapeutic options are shown the psychotherapeutic treatments from the tendencies of conduction, topic agents based in their majority on spray and creams with anesthetics components and other systemic treatments mainly based on anesthetics and ant depressive, as well as , the combination of methods and several pharmacs getting then greater levels of effectiveness. Finally, it is proposed the antidepressive Dapoxetine that shows good level of response. In the these paper was done a review of the theme deeping in aspect related with the masculine sexual answer and its treatment. With this objective the more updated works published in Pubmed and Medline were reviewed. Conclusions: The premature ejaculation is a world problem and although the several variables of treatment is still a masculine resistance to accept it as a disorder and therefore to its treatment. The SRSI and specially Dapoxetine constitute a variable of an effective treatmen(AU)